WorldCat Identities

Shaw, James W.

Overview
Works: 16 works in 29 publications in 1 language and 945 library holdings
Genres: Academic theses 
Roles: Author
Publication Timeline
.
Most widely held works by James W Shaw
An evaluation of shock incarceration in Louisiana by Doris L MacKenzie( Book )

3 editions published in 1993 in English and held by 460 WorldCat member libraries worldwide

The Kansas City gun experiment by Lawrence W Sherman( Book )

3 editions published in 1995 in English and held by 432 WorldCat member libraries worldwide

Shock Incarceration in Louisiana, 1987-1989 by Doris L MacKenzie( )

6 editions published in 1993 in English and No Linguistic content and held by 34 WorldCat member libraries worldwide

These data describe the results of one component of an evaluation of the ''shock incarceration'' program in the Louisiana Department of Public Safety and Corrections (LDPSC). This program, formally called IMPACT (Intensive Motivational Program of Alternative Correctional Treatment), began in 1987 and consisted of two phases. In the first phase offenders spent 90 to 180 days in a medium security prison participating in a rigorous boot camp-type program. Offenders who successfully completed the program were released from prison and placed under intensive supervision in the community--the second phase of the program. Changes in offender behavior and attitudes during the prison and community supervision phases of the shock program were examined in a quasi-experimental design to determine the impact of the program on the individual offenders. Comparisons were made with similar offenders who were not in the shock program who had been sentenced to prison and parole/probation. Shock and nonshock incarcerated offenders were asked to complete self-report questionnaires. Information was also collected from LDPSC records and from monthly parole performance evaluations completed by parole and probation officers. Information collected from LDPSC records included demographics, sentence characteristics, release date, offense, criminal history, I.Q. (Beta II) and MMPI scores, and diagnostic personnel evaluations of mental health, substance abuse, general attitude, adjustment, and violence potential. Part 1 of the collection consists of inmate data collected from the incarcerated shock program participants (N = 208) and the incarcerated nonshock offenders (N = 98, with partial records for an additional 46). Information includes police record data, clinical diagnostic data, offender's self-reported demographic data, scales for self-reported attitudes and personality measures, and offend ... Cf.: http://webapp.icpsr.umich.edu/cocoon/ICPSR-STUDY/09926.xml
Community policing against crime : violence and firearms by James W Shaw( )

3 editions published in 1994 in English and held by 5 WorldCat member libraries worldwide

An evaluation of shock incarceration in Louisiana by Doris L MacKenzie( Book )

2 editions published in 1990 in English and held by 2 WorldCat member libraries worldwide

An evaluation of shock incarceration in Louisiana by Doris L MacKenzie( Book )

1 edition published in 1993 in English and held by 2 WorldCat member libraries worldwide

A computer approach to performing MPPA testing by James W Shaw( )

2 editions published in 1976 in English and held by 2 WorldCat member libraries worldwide

In the highly competitive cattle market of today a scientific method, by which a rancher can base a judgement, moderated by experience as to which animals are to be kept, as proven by superior performance, can be a valuable asset. This record performance testing system was designed to demonstrate the value of adequately kept records. Its purpose is to help ranchers develop records of herd performance, inventory, and improve management practices by more informed decisions. The system, through its representative, provides a means by which ranchers can obtain information on new ideas in animal production, health, sanitation, nutrition, management practices, and new record testing methods showing the results of their use and meaning. The procedure used is based on the recommendations of the Beef Improvement Federation. The three test result summaries printed are (1) Weaning; (2) Yearling; and (3) Dam. An inventory of the herd is generated showing, in addition to performance, those not producing a calf, and those calves which did not have enough data for processing. The test results will list different amounts of valuable information. According to each individual test, the results are:(1) Weaning: The calf's weight both actual and adjusted, (two hundred five (205) days of age), wean weight ratio, and weight per day of age at weaning. Also provided is a ranking of best to worst, by actual and adjusted weight.(2) Yearling: Lists weight, actual and adjusted (one hundred sixty days between wean and year dates), weight gained between wean and year tests, average daily gain, and weight per day of age at yearling. Ranking of best to worst is of two kinds by actual yearling weight and by adjusted yearling weight.(3) Dam: Number of calves in record, total mean weight accumulated, and previous Most Probably Producing Ability (MPPA) score. There is a ranking of best dam to worst dam, based on current MPPA scores. All the test results included herd averages for most valuable data (i.e.; weight, MPAA score etc.). This is but one type of a computer method of handling a cattle record system. The system was programmed and placed in operation, limited only by the physical size of the computer at the time of its programming. The system is in operation on the Burroughs 6700 computer system at the Utah State University campus. This full system was accomplished by first modifying the calf performance testing and then programming the MPPA testing routines
The productivity of pharmaceuticals in improving health: an analysis of the OECD health data by James W Shaw( )

1 edition published in 2002 in English and held by 1 WorldCat member library worldwide

The Rempel genealogy : beginning with Johann Rempel, approximately 1830-1973 by LaVerna Penner Shaw( Book )

1 edition published in 1973 in English and held by 1 WorldCat member library worldwide

Johann Rempel was born 25 February 1830 in Pordenau, South Russia. He came to the United States in 1874 and settled in Kansas
Coal liquids subsidies by James W Shaw( )

1 edition published in 1980 in English and held by 1 WorldCat member library worldwide

The way ahead for joint transformation by James W Shaw( )

1 edition published in 2003 in English and held by 1 WorldCat member library worldwide

Transformation is a central theme of current national security policy. Although OSD is firmly committed to change, the way ahead is unclear. Each Service is now pursuing its own version of transformation. Expected OSD guidance will cover transformation tenets, but will not provide the detailed approach required to determine which programs are indeed transformational and their impact to warfighting capability. What is needed is the newly approved JROC joint operational concept and detailed integrated architecture approach to provide a common framework for discussion and the ability to design an interoperable force structure meeting JV 2020 objectives. In addition, a method is needed to effectively describe and implement interfaces in U.S. and foreign information and weapon systems that do not exist today
The Kansas City gun experiment by National Institute of Justice (U.S.)( Book )

1 edition published in 1995 in English and held by 1 WorldCat member library worldwide

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Background: Patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck have few treatment options and poor prognosis. Nivolumab significantly improved survival of this patient population when compared with standard single-agent therapy of investigator's choice in Checkmate 141; here we report the effect of nivolumab on patient-reported outcomes (PROs). Methods: CheckMate 141 was a randomised, open-label, phase 3 trial in patients with recurrent or metastatic squamous cell carcinoma of the head and neck who progressed within 6 months after platinum-based chemotherapy. Patients were randomly assigned (2:1) to nivolumab 3 mg/kg every 2 weeks (n=240) or investigator's choice (n=121) of methotrexate (40–60 mg/m 2 of body surface area), docetaxel (30–40 mg/m 2 ), or cetuximab (250 mg/m 2 after a loading dose of 400 mg/m 2 ) until disease progression, intolerable toxicity, or withdrawal of consent. On Jan 26, 2016, the independent data monitoring committee reviewed the data at the planned interim analysis and declared overall survival superiority for nivolumab over investigator's choice therapy (primary endpoint; described previously). The protocol was amended to allow patients in the investigator's choice group to cross over to nivolumab. All patients not on active therapy are being followed for survival. As an exploratory endpoint, PROs were assessed at baseline, week 9, and every 6 weeks thereafter using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire–Core 30 (QLQ-C30), the EORTC head and neck cancer-specific module (EORTC QLQ-H&N35), and the three-level European Quality of Life–5 Dimensions (EQ-5D) questionnaire. Differences within and between treatment groups in PROs were analysed by ANCOVA among patients with baseline and at least one other assessment. All randomised patients were included in the time to clinically meaningful deterioration analyses. Median time to clinically meaningful deterioration was analysed by Kaplan-Meier methods. CheckMate 141 was registered withClinicalTrials.org, numberNCT02105636 . Findings: Patients were enrolled between May 29, 2014, and July 31, 2015, and subsequently 361 patients were randomly assigned to receive nivolumab (n=240) or investigator's choice (n=121). Among them, 129 patients (93 in the nivolumab group and 36 in the investigator's choice group) completed any of the PRO questionnaires at baseline and at least one other assessment. Treatment with nivolumab resulted in adjusted mean changes from baseline to week 15 ranging from −2·1 to 5·4 across functional and symptom domains measured by the EORTC QLQ-C30, with no domains indicating clinically meaningful deterioration. By contrast, eight (53%) of the 15 domains in the investigator's choice group showed clinically meaningful deterioration (10 points or more) at week 15 (change from baseline range, −24·5 to 2·4). Similarly, on the EORTC QLQ-H&N35, clinically meaningful worsening at week 15 was seen in no domains in the nivolumab group and eight (44%) of 18 domains in the investigator's choice group. Patients in the nivolumab group had a clinically meaningful improvement (according to a difference of 7 points or greater) in adjusted mean change from baseline to week 15 on the EQ-5D visual analogue scale, in contrast to a clinically meaningful deterioration in the investigator's choice group (7·3 vs −7·8). Differences between groups were significant and clinically meaningful at weeks 9 and 15 in favour of nivolumab for role functioning, social functioning, fatigue, dyspnoea, and appetite loss on the EORTC QLQ-C30 and pain and sensory problems on the EORTC QLQ-H&N35. Median time to deterioration was significantly longer with nivolumab versus investigator's choice for 13 (37%) of 35 domains assessed across the three questionnaires. Interpretation: In this exploratory analysis of CheckMate 141, nivolumab stabilised symptoms and functioning from baseline to weeks 9 and 15, whereas investigator's choice led to clinically meaningful deterioration. Nivolumab delayed time to deterioration of patient-reported quality-of-life outcomes compared with single-agent therapy of investigator's choice in patients with platinum-refractory recurrent or metastatic squamous cell carcinoma of the head and neck. In view of the major unmet need in this population and the importance of maintaining or improving quality of life for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, these data support nivolumab as a new standard-of-care option in this setting. Funding: Bristol-Myers Squibb
Feasibility of alternative cooling systems for power plants in the northern Great Plains by Bruce A Tichenor( Book )

1 edition published in 1974 in English and held by 0 WorldCat member libraries worldwide

 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.48 (from 0.44 for The Kansas ... to 1.00 for Feasibilit ...)

Languages
English (27)